Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) has issued a stock trading risk warning announcement, stating that it is a CRO enterprise primarily focused on the research and development of small molecule chemical generic drugs. Its main business involves providing clients with a comprehensive "one-stop" full-process service for drug research and registration, mainly centered on small molecule chemical generics. The majority of its research projects come from client commissions, supplemented by some in-house initiatives, and it does not engage in innovative drug research and development.